Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR.

J Thorac Oncol. 2014 Mar;9(3):e21-3. doi: 10.1097/JTO.0000000000000013. No abstract available.

2.

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol. 2012 Dec;7(12):e36-8. doi: 10.1097/JTO.0b013e318274694e. No abstract available.

3.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

4.

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.

Shan L, Jiang P, Xu F, Zhang W, Guo L, Wu J, Zeng Y, Jiao Y, Ying J.

J Thorac Oncol. 2015 Jun;10(6):e37-9. doi: 10.1097/JTO.0000000000000467. No abstract available.

5.

Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.

Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC.

J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b. No abstract available.

6.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, Soussan-Gutman L, Otto GA, Stephens PJ, Ross JS, Cronin MT, Lipson D, Miller VA.

J Thorac Oncol. 2012 Sep;7(9):e14-6. doi: 10.1097/JTO.0b013e3182614ab5. No abstract available.

7.

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038. No abstract available.

8.

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.

9.

An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.

Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.

J Thorac Oncol. 2016 Dec;11(12):2248-2252. doi: 10.1016/j.jtho.2016.08.139. Epub 2016 Sep 6.

10.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, Soria JC, Vielh P, Besse B, Farace F.

J Clin Oncol. 2013 Jun 20;31(18):2273-81. doi: 10.1200/JCO.2012.44.5932. Epub 2013 May 13.

PMID:
23669222
11.

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH.

J Thorac Oncol. 2011 Mar;6(3):466-72. doi: 10.1097/JTO.0b013e31820b82e8.

12.

Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.

Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T.

Arch Pathol Lab Med. 2014 Jun;138(6):794-802. doi: 10.5858/arpa.2012-0762-OA.

PMID:
24878018
13.

Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.

To KF, Tong JH, Yeung KS, Lung RW, Law PP, Chau SL, Kang W, Tong CY, Chow C, Chan AW, Leung LK, Mok TS.

J Thorac Oncol. 2013 Jul;8(7):883-91. doi: 10.1097/JTO.0b013e3182904e22.

14.

ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.

Incharoen P, Reungwetwattana T, Saowapa S, Kamprerasart K, Pangpunyakulchai D, Arsa L, Jinawath A.

World J Surg Oncol. 2016 May 3;14:139. doi: 10.1186/s12957-016-0893-6.

15.

Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.

Gruber K, Horn H, Kalla J, Fritz P, Rosenwald A, Kohlhäufl M, Friedel G, Schwab M, Ott G, Kalla C.

J Thorac Oncol. 2014 Mar;9(3):307-15. doi: 10.1097/JTO.0000000000000068.

16.

Prospective screening for ALK: clinical features and outcome according to ALK status.

Fallet V, Cadranel J, Doubre H, Toper C, Monnet I, Chinet T, Oliviero G, Foulon G, De Cremoux H, Vieira T, Antoine M, Wislez M.

Eur J Cancer. 2014 May;50(7):1239-46. doi: 10.1016/j.ejca.2014.02.001. Epub 2014 Feb 28.

PMID:
24589437
17.

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.

Cancer. 2012 Sep 15;118(18):4486-94. doi: 10.1002/cncr.27411. Epub 2012 Jan 26.

18.

Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study.

Zwaenepoel K, Merkle D, Cabillic F, Berg E, Belaud-Rotureau MA, Grazioli V, Herelle O, Hummel M, Le Calve M, Lenze D, Mende S, Pauwels P, Quilichini B, Repetti E.

Exp Mol Pathol. 2015 Feb;98(1):113-8. doi: 10.1016/j.yexmp.2015.01.005. Epub 2015 Jan 8.

19.

Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.

Toyokawa G, Takenoyama M, Watanabe S, Toyozawa R, Inamasu E, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Ichinose Y.

J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed. No abstract available.

20.

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.

Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, Begueret H, Grégoire V, Hofman P, Gros A, Garcia S, Monhoven N, Devouassoux-Shisheboran M, Mansuet-Lupo A, Thivolet F, Antoine M, Vignaud JM, Penault-Llorca F, Galateau-Sallé F, McLeer-Florin A.

Eur Respir J. 2015 Jul;46(1):207-18. doi: 10.1183/09031936.00119914. Epub 2015 Apr 30.

Supplemental Content

Support Center